Seeking impartial news? Meet 1440.

Every day, 3.5 million readers turn to 1440 for their factual news. We sift through 100+ sources to bring you a complete summary of politics, global events, business, and culture, all in a brief 5-minute email. Enjoy an impartial news experience.

Join for free today!

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1900+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Idorsia's TRYVIO (targetiong ETAxETB) gets FDA label update removing REMS for systemic hypertension treatment
Small molecule, hypertension, risk evaluation and mitigation strategy (REMS) - Read more

THE GOOD
Clinical Trials

Cytora's hOMSC200 shows safety and superior efficacy in Ph1/2a trial with 53% wound closure rate in diabetic foot ulcuers
Stem cell-derived therapy, allogeneic cell therapy, cell therapy, diabetic foot ulcers - Read more

RemeGen's telitacicept (targeting BlySxAPRIL) shows efficacy in Ph3 trial for generalized myasthenia gravis.
Fusion protein, myasthenia gravis - Read more

Phio Pharmaceuticals' INTASYL PH-762 advances to fourth dose cohort after positive Ph1b safety data in various skin cancers
siRNA, squamous cell carcinoma, Merkel cell carcinoma, melanoma - Read more

Ractigen's RAG-01 (targeting p21 tumor suppressor gene) shows 66.7% complete response in Ph1 trial for non-muscle invasive bladder cancer patients
saRNA, bladder cancer - Read more

PRESENTED BY TLDR BIOTECH
What would you do with 7k+ meticulously tagged biotech & pharma data points?
Free gene-editing data set below!

Over the past year, TLDR Biotech has been collecting and categorizing industry news across approvals, clinical trials, fundraises, partnerships, M&A, politics & policy, and much much more.

Each data point is tagged by drug modality, disease indication, tech area, and even more specific categories. For example:

🔍 Need to track all small molecule fundraises across oncology?

📈 Want a curated list of recent cell therapy clinical trials updates (both the successes and failures)?

💡 Looking for trends in Alzheimer's and Parkinson's disease partnerships?

Here’s a free set of data - gene-editing stories over the last 4 months.

We’re leveraging this resource to build tailored reports and curated insights for select clients—and now you can get full access.

Ready to get access or have questions? Check out our landing page.

✅ More Good News ✅

THE GOOD
Earnings & Finances

Ferring’s 2024 revenue reached €2.3 billion, driven by strong Reproductive Medicine sales and Adstiladrin's first full year on market
Big pharma earnings, gene therapy, bladder cancer - Read more

THE GOOD
Fundraises

Solu Therapeutics $41M Series A, developing STX-0712 (targeting CCR2) for chronic myelomonocytic leukaemia treatment
Small molecule-antibody conjugate, leukemia, cancer - Read more

Vaxess Technologies $9M funding, advancing microarray patch technology for home delivery of GLP-1 therapies
Microarray, drug delivery - Read more

Immunic $5.1M registered direct offering, biotech developing clinical pipeline for chronic inflammatory and autoimmune diseases
Small molecule, multiple sclerosis (MS), ulcerative colitis - Read more

SecondWave Systems $7M Series A, developing wearable ultrasound stimulation technology to treat inflammatory disease
Medical device, ultrasound, inflammatory disease - Read more

THE GOOD
Investments

DHL Group to invest US$2.2B globally to enhance healthcare logistics infrastructure, technology, and supply chains through 2030
Supply chain, logistics - Read more

THE GOOD
Lawsuits

Jazz Pharmaceuticals settles $145M anti-trust lawsuit regarding narcolepsy drug Xyrem, denies wrongdoing
Antitrust, generic, small molecule, narcolepsy, cataplexy - Read more

Bristol Myers Squibb wins dismissal of class action lawsuit alleging anticompetitive tactics to protect Pomalyst from generic competition
Antitrust, small molecule, multiple myeloma, cancer - Read more

THE GOOD
Mergers & Acquisitions

PharmaLogic acquiring majority stake in Agilera from IFE, creating global radiopharmaceutical-focused CDMO
CDMO (Contract Development & Manufacturing Organization), radiopharm, radiopharm manufacturing - Read more

THE GOOD
Partnerships

AmacaThera, undisclosed global pharma partner, developing single-injection long-acting biologic using AmacaGel hydrogel delivery platform
Drug delivery, hydrogel, drug formulation, drug development - Read more

Worldwide Clinical Trials, NetraMark partnership employs NetraAI to identify hidden patient subpopulations for optimized clinical trials
CRO (Contract Research Organization), AI, clinical trial enrolment - Read more

Ebenbuild, Palvella Therapeutics using AI-powered digital twin lung simulations to study PRS-220 aerosol delivery in IPF patients
Protein, pulmonary fibrosis, drug delivery, inhaled therapy - Read more

THE GOOD
Patient Access

ICER suggests federal policy changes to increase access to GLP-1 obesity drugs amid rising Medicare costs
Drug Pricing, drug access, obesity, GLP-1 - Read more

THE GOOD
Politics & Policy

President Trump’s 90-day tariff pause sparks market rally (for now)
Tariffs - Read more

THE GOOD
Research

University of Galway study finds GLP-1s may reduce dementia risk, while other glucose-lowering therapies don't
Dementia, GLP-1 - Read more

Studies identify blood biomarker and potential amitriptyline (targeting SERT, NET) treatment for mild traumatic brain injury, offering new recovery insights
Small molecule, traumatic brain injury, biomarker - Read more

Researchers developed a vaccine-probiotic combination that prevents and treats bacterial gut infections in mice, potentially reducing antibiotics use
Vaccine, probiotic, bacterial infection, antibiotic resistance - Read more

PRESENTED BY YOU?
Get the attention of 1900+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Company Shutdown

Vincerx Pharma to wind down after failed merger with QumulusAI; third times isn’t the charm
Antibody-drug conjugate (ADC), AI, cancer, leukemia, myelodysplastic syndrome - Read more

THE BAD
IPOs

Stada delays Frankfurt IPO due to U.S. tariffs, market volatility, and geopolitical uncertainties, new date under evaluation
Big pharma strategy - Read more

THE BAD
Layoffs

PacBio cutting workforce and spending due to global tariffs and threats to research grants, with 5% revenue decline
DNA sequencing, next-generation sequencing (NGS) - Read more

Reckitt is laying off 190 staff at its New Jersey headquarters as part of restructuring
Consumer health, over-the-counter - Read more

THE BAD
Politics & Policy

HHS targets 35% reduction in contract spending across all agencies, with 334 contracts already terminated
US Department of Health & Human Services (HHS), federal funding - Read more

THE UGLY
Politics & Policy

Trump plans major tariffs on pharmaceuticals to incentivize companies to relocate production to the US market
Tariffs - Read more

Appeals court allows HHS and 19 agencies to fire probationary workers, overturning lower court order
US Department of Health & Human Services (HHS), public agency layoffs - Read more

Federal funding freeze hits Cornell and Northwestern over antisemitism probes, jeopardizing vital health and scientific research projects
Federal funding, federal research funding - Read more

THE UGLY
Public Health

U.S. maternal mortality rose 27% over five years, prompting urgent calls for increased investment amid CDC funding cuts
Women's health, maternal mortality - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here